⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233477 | 0.54 | — | — | |
| SCHEMBL3894641 | 0.47 | — | — | |
| SCHEMBL380648 | 0.44 | — | — | |
| SCHEMBL193794 | 0.44 | — | — | |
| SCHEMBL8802218 | 0.42 | — | — | |
| SCHEMBL102953 | 0.35 | — | — | |
| SCHEMBL166940 | 0.34 | — | — | |
| SCHEMBL2295963 | 0.34 | — | — | |
| SCHEMBL12992748 | 0.34 | — | — | |
| SCHEMBL4056 | 0.31 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429354-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | Chromadex Inc. (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017161165-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | WO | claimed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | claimed |
| WO-2016123709-A1 | FLUORINATED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS INHIBITORS OF BROMODOMAIN CONTAINING PROTEINS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | claimed |
| EP-2627178-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | claimed |
| EP-1940817-B1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | GALANTOS PHARMA GMBH (DE) | 2010-07-07 | — | — | EP | claimed |
| US-20090253654-A1 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | GALANTOS PHARMA GMBH (DE) | 2009-10-08 | — | — | US | claimed |
| EP-1613318-A4 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080261954-A1 | Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment | GALANTOS PHARMA GMBH (DE) | 2008-10-23 | — | — | US | claimed |
| EP-1613318-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004087880-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1261731-A1 | CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS | Urtti, Arto (FI) | 2002-12-04 | — | — | EP | claimed |
| WO-2001062946-A1 | CATIONIC AMPHIPHILIC 1,4-DIHYDROPYRIDINE DERIVATIVES USEFUL FOR DELIVERY OF NUCLEOTIDE CONTAINING COMPOUNDS | URTTI ARTO (FI) | 2001-08-30 | — | — | WO | claimed |
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-1998001423-A1 | 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| EP-0755931-A1 | Dihydropyridine and pyridine derivatives and process for their preparation | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-01-29 | — | — | EP | disclosed |
| US-5576439-A | Dihydropyridinecarboxylic acid anhydrides | CIBA-GEIGY CORPORATION (US) | 1996-11-19 | — | — | US | disclosed |